JP7385658B2 - Ｃｄｋ９活性を調節するための化合物、組成物、および方法 - Google Patents

Ｃｄｋ９活性を調節するための化合物、組成物、および方法 Download PDF

Info

Publication number
JP7385658B2
JP7385658B2 JP2021521232A JP2021521232A JP7385658B2 JP 7385658 B2 JP7385658 B2 JP 7385658B2 JP 2021521232 A JP2021521232 A JP 2021521232A JP 2021521232 A JP2021521232 A JP 2021521232A JP 7385658 B2 JP7385658 B2 JP 7385658B2
Authority
JP
Japan
Prior art keywords
mmol
pyrimidin
reaction mixture
cdk9
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021521232A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505268A5 (https=
JP2022505268A (ja
Inventor
ピーター ミコチク
ジョセフ ヴァッカ
デイビッド フリーマン
アンドリュー タスカー
Original Assignee
クロノス バイオ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クロノス バイオ インコーポレイテッド filed Critical クロノス バイオ インコーポレイテッド
Publication of JP2022505268A publication Critical patent/JP2022505268A/ja
Publication of JP2022505268A5 publication Critical patent/JP2022505268A5/ja
Application granted granted Critical
Publication of JP7385658B2 publication Critical patent/JP7385658B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021521232A 2018-10-30 2019-10-29 Ｃｄｋ９活性を調節するための化合物、組成物、および方法 Active JP7385658B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862752635P 2018-10-30 2018-10-30
US62/752,635 2018-10-30
US201962884993P 2019-08-09 2019-08-09
US62/884,993 2019-08-09
US201962910058P 2019-10-03 2019-10-03
US62/910,058 2019-10-03
PCT/US2019/058482 WO2020092314A1 (en) 2018-10-30 2019-10-29 Compounds, compositions, and methods for modulating cdk9 activity

Publications (3)

Publication Number Publication Date
JP2022505268A JP2022505268A (ja) 2022-01-14
JP2022505268A5 JP2022505268A5 (https=) 2022-10-31
JP7385658B2 true JP7385658B2 (ja) 2023-11-22

Family

ID=70328627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521232A Active JP7385658B2 (ja) 2018-10-30 2019-10-29 Ｃｄｋ９活性を調節するための化合物、組成物、および方法

Country Status (21)

Country Link
US (3) US11155560B2 (https=)
EP (1) EP3873911A4 (https=)
JP (1) JP7385658B2 (https=)
KR (2) KR20250174699A (https=)
CN (1) CN112996790B (https=)
AU (1) AU2019370200B2 (https=)
BR (1) BR112021008176A2 (https=)
CA (1) CA3118472A1 (https=)
CO (1) CO2021005502A2 (https=)
CR (1) CR20210202A (https=)
DO (1) DOP2021000066A (https=)
IL (1) IL282254B2 (https=)
MA (1) MA54092A (https=)
MD (1) MD20210033A2 (https=)
MX (1) MX2021004769A (https=)
MY (1) MY210039A (https=)
PE (1) PE20212196A1 (https=)
PH (1) PH12021550857A1 (https=)
SG (1) SG11202104229WA (https=)
WO (1) WO2020092314A1 (https=)
ZA (1) ZA202102609B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11155560B2 (en) * 2018-10-30 2021-10-26 Kronos Bio, Inc. Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity
US20230158159A1 (en) * 2020-04-24 2023-05-25 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
JP7814386B2 (ja) * 2020-11-05 2026-02-16 クロノス バイオ インコーポレイテッド Ｃｄｋ９活性を調節するための化合物および方法
EP4282868B1 (en) * 2021-01-22 2026-03-04 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Substituted pyrazolo[1,5-a]pyrimidine-7-amine derivative, and compositions and medical use thereof
JP2024543136A (ja) * 2021-11-24 2024-11-19 クロノス バイオ インコーポレイテッド （１Ｓ，３Ｓ）－Ｎ１－（５－（ペンタン－３－イル）ピラゾロ［１，５－ａ］ピリミジン－７－イル）シクロペンタン－１，３－ジアミンの多形性形態および塩形態
JP2025527161A (ja) * 2022-07-22 2025-08-20 上海海雁醫藥科技有限公司 置換されたピラゾロ［１，５－ａ］ピリミジン－７－アミン誘導体の薬学的に許容される塩および多形体、ならびにその使用
WO2025153034A1 (zh) * 2024-01-19 2025-07-24 上海海雁医药科技有限公司 一种吡唑并嘧啶衍生物的磷酸盐多晶型物及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087707A1 (en) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JP2006502184A (ja) 2002-09-04 2006-01-19 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしての新規ピラゾロピリミジン
JP2006502163A (ja) 2002-09-04 2006-01-19 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP2009511487A (ja) 2005-10-06 2009-03-19 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしての新規ピラゾロピリミジン
JP2010505839A (ja) 2006-10-04 2010-02-25 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターのピラゾロピリミジン
JP2010529140A (ja) 2007-06-05 2010-08-26 エモリー・ユニバーシテイ サイクリン依存性キナーゼの選択的阻害剤
JP2011526931A (ja) 2008-07-03 2011-10-20 エグゼリクシス， インコーポレイテッド Ｃｄｋモジュレーター
JP2017506250A (ja) 2014-02-21 2017-03-02 キャンサー・リサーチ・テクノロジー・リミテッド Ｃｄｋ阻害剤としてのピラゾロ［１，５‐ａ］ピリミジン‐５，７‐ジアミン化合物及びその治療用途
JP2018515434A (ja) 2015-03-27 2018-06-14 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389632A (en) 1992-02-24 1995-02-14 Laboratoires Upsa Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
WO1995035298A1 (en) 1994-06-21 1995-12-28 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE
HU229024B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
CA2379585C (en) 1999-09-30 2006-06-20 James W. Darrow Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
ES2277855T3 (es) 1999-09-30 2007-08-01 Neurogen Corporation Pirazolo-(1,5-a)-1,5-pirimidinas y pirazolo-(1,5-a)-1,3,5-triazinas amino sustituidas.
JP2002308879A (ja) 2001-04-13 2002-10-23 Nippon Soda Co Ltd ５−ハロアルキル−アゾロピリミジン化合物、製造方法及び有害生物防除剤
US7662826B2 (en) 2002-04-23 2010-02-16 Shionogi & Co., Ltd. Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
JP2005529919A (ja) 2002-05-10 2005-10-06 スミスクライン ビーチャム コーポレーション 治療用化合物
AU2003240488A1 (en) 2002-06-04 2003-12-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
GB0305559D0 (en) 2003-03-11 2003-04-16 Teijin Ltd Compounds
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
US7501405B2 (en) 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
US20070060595A1 (en) 2003-10-10 2007-03-15 Toshio Yoshizawa Novel fused heterocyclic compound and use thereof
JP2007515474A (ja) 2003-12-22 2007-06-14 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
US8018479B2 (en) 2008-08-27 2011-09-13 Lexmark International, Inc. Method and system for correcting the linearity error in electrophotographic devices
WO2006016715A1 (ja) * 2004-08-13 2006-02-16 Teijin Pharma Limited ピラゾロ［１，５－ａ］ピリミジン誘導体
CA2591125A1 (en) 2004-12-21 2006-06-29 Schering Corporation Pyrazolo[1,5-a]pyrimidine adenosine a2a receptor antagonists
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
AR057979A1 (es) 2005-10-06 2008-01-09 Schering Corp PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS.
BRPI0616985B1 (pt) 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
AR056876A1 (es) 2005-10-21 2007-10-31 Tanabe Seiyaku Co Compuestos de pirazolo[1-5-a]pirimidina, antagonistas de receptores canabinoides cb1, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades del sistema nervioso central, tales como trastornos psicoticos, neurologicos y similares
WO2007109571A2 (en) 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
WO2007139732A1 (en) 2006-05-22 2007-12-06 Schering Corporation Pyrazolo [1, 5-a] pyrimidines as cdk inhibitors
CN101784276A (zh) 2007-06-27 2010-07-21 传染性疾病研究院 化合物在用于制备抗结核药剂中的用途
JP5578490B2 (ja) 2008-12-26 2014-08-27 味の素株式会社 ピラゾロピリミジン化合物
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
JP5802676B2 (ja) 2009-12-04 2015-10-28 センワ バイオサイエンシズ インコーポレイテッド Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
ES2540867T3 (es) 2010-02-26 2015-07-14 Mitsubishi Tanabe Pharma Corporation Compuestos de pirazolopirimidina y su uso como inhibidores de PDE10
MY183861A (en) 2010-03-05 2021-03-17 Kyowa Hakko Kirin Co Ltd Pyrazolopyrimidine derivative
PT3012258T (pt) 2010-06-24 2018-12-14 Gilead Sciences Inc Composição farmacêutica compreendendo um derivado de pirazolo[1,5-a]pirimidina como agente antiviral
CN110003219A (zh) 2010-07-13 2019-07-12 弗·哈夫曼-拉罗切有限公司 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012044562A2 (en) 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde10 inhibitors
WO2012170827A2 (en) 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
WO2013104611A1 (en) 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted pyrazolopyrimidines as akt kinase inhibitors
CN104136399B (zh) 2012-02-17 2018-08-07 米伦纽姆医药公司 泛素活化酶的吡唑并嘧啶基抑制剂
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
CA2889919C (en) 2012-11-16 2021-08-17 University Health Network Pyrazolopyrimidine compounds
BR112015022864A8 (pt) 2013-03-14 2019-11-26 Celtaxsys Inc composto, composição farmacêutica e uso dos mesmos
EP3125907A4 (en) 2014-04-01 2017-11-29 Cornell University Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
EP3129371B1 (en) 2014-04-05 2020-07-29 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
ES2899196T3 (es) 2015-03-09 2022-03-10 Aurigene Discovery Tech Ltd Derivados de pirazolo[1,5-a][1,3,5]triazina y de pirazolo[1,5-a]pirimidina como inhibidores de CDK
WO2016169995A1 (en) 2015-04-20 2016-10-27 AbbVie Deutschland GmbH & Co. KG Substituted pyrazolopyrimidines and method of use
WO2016201370A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP3356330B1 (en) 2015-10-01 2019-11-20 Bristol-Myers Squibb Company Biaryl kinase inhibitors
JP2018199623A (ja) 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
US11112410B2 (en) 2016-04-13 2021-09-07 President And Fellows Of Harvard College Methods for capturing, isolation, and targeting of circulating tumor cells and diagnostic and therapeutic applications thereof
US20190060296A1 (en) * 2017-07-28 2019-02-28 Massachusetts Institute Of Technology Discovery of small molecules that target the androgen receptor and uses
SI3658557T1 (sl) 2017-07-28 2024-10-30 Takeda Pharmaceutical Company Limited Zaviralci TYK2 in njihova uporaba
US11155560B2 (en) * 2018-10-30 2021-10-26 Kronos Bio, Inc. Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502184A (ja) 2002-09-04 2006-01-19 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしての新規ピラゾロピリミジン
JP2006502163A (ja) 2002-09-04 2006-01-19 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
WO2004087707A1 (en) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JP2009511487A (ja) 2005-10-06 2009-03-19 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしての新規ピラゾロピリミジン
JP2010505839A (ja) 2006-10-04 2010-02-25 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターのピラゾロピリミジン
JP2010529140A (ja) 2007-06-05 2010-08-26 エモリー・ユニバーシテイ サイクリン依存性キナーゼの選択的阻害剤
JP2011526931A (ja) 2008-07-03 2011-10-20 エグゼリクシス， インコーポレイテッド Ｃｄｋモジュレーター
JP2017506250A (ja) 2014-02-21 2017-03-02 キャンサー・リサーチ・テクノロジー・リミテッド Ｃｄｋ阻害剤としてのピラゾロ［１，５‐ａ］ピリミジン‐５，７‐ジアミン化合物及びその治療用途
JP2018515434A (ja) 2015-03-27 2018-06-14 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤

Also Published As

Publication number Publication date
CN112996790A (zh) 2021-06-18
AU2019370200B2 (en) 2024-12-19
ZA202102609B (en) 2023-02-22
AU2019370200A1 (en) 2021-06-10
MA54092A (fr) 2021-09-08
MX2021004769A (es) 2021-08-24
KR20210068597A (ko) 2021-06-09
MD20210033A2 (ro) 2021-10-31
US11155560B2 (en) 2021-10-26
PE20212196A1 (es) 2021-11-16
IL282254A (en) 2021-05-31
KR20250174699A (ko) 2025-12-12
US20200131189A1 (en) 2020-04-30
US20240132506A1 (en) 2024-04-25
US11845754B2 (en) 2023-12-19
CA3118472A1 (en) 2020-05-07
US20220002305A1 (en) 2022-01-06
DOP2021000066A (es) 2021-10-31
WO2020092314A1 (en) 2020-05-07
CN112996790B (zh) 2023-11-03
EP3873911A1 (en) 2021-09-08
PH12021550857A1 (en) 2021-12-06
EP3873911A4 (en) 2022-06-22
IL282254B2 (en) 2025-08-01
JP2022505268A (ja) 2022-01-14
IL282254B1 (en) 2025-04-01
MY210039A (en) 2025-08-22
CO2021005502A2 (es) 2021-09-20
SG11202104229WA (en) 2021-05-28
BR112021008176A2 (pt) 2021-08-03
CR20210202A (es) 2022-02-08

Similar Documents

Publication Publication Date Title
JP7385658B2 (ja) Ｃｄｋ９活性を調節するための化合物、組成物、および方法
US8653064B2 (en) Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate
JP2022546520A (ja) Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
CN102083429B (zh) Ido抑制剂
CN114867726A (zh) Kras g12c突变体的小分子抑制剂
CN109311894B (zh) 作为激酶抑制剂的n-(取代的-苯基)-磺酰胺衍生物
JP2023501399A (ja) ヘテロ環式ｒｉｐ１阻害化合物
JP2020528062A (ja) ピペラジンヘテロアリール誘導体、その製造方法、およびその医薬での使用
CN102171214A (zh) 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
UA111739C2 (uk) Імідазопіридазини як інгібітори аkt-кінази
TWI716976B (zh) 高活性sting蛋白激動劑
US20180215738A1 (en) Inhibitors of ack1/tnk2 tyrosine kinase
CN103370321B (zh) 取代的嘧啶并[1,2-b]吲唑及其作为PI3K/AKT途径的调节剂的用途
WO2023179078A1 (zh) 咪唑并[1,2-a]吡嗪或吡唑并[1,5-a]嘧啶衍生物及其用途
CN117003754A (zh) 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途
OA20540A (en) Compounds, compositions, and methods for modulating CDK9 activity.
EA043715B1 (ru) Соединения, композиции и способы модуляции активности cdk9
TW201910333A (zh) 哌嗪并雜芳基類衍生物、其製備方法及其在醫藥上的應用
WO2022257732A1 (zh) 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用
EA048203B1 (ru) Соединения, ингибирующие rip1, и способы их получения и применения
HK1146273B (en) Fused bicyclic pyrimidines
HK1146273A1 (en) Fused bicyclic pyrimidines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221021

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230522

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231012

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231023

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231110

R150 Certificate of patent or registration of utility model

Ref document number: 7385658

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150